Alveolar macrophage activation after trauma-hemorrhage and sepsis is dependent on NF-kappaB and MAPK/ERK mechanisms

Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L799-805. doi: 10.1152/ajplung.00465.2001.

Abstract

The acute respiratory distress syndrome (ARDS) is a major cause of morbidity after injury. We hypothesized that alveolar macrophage (AMPhi) chemokine and cytokine release after hemorrhage and sepsis is regulated by NF-kappaB and MAPK. Adult male rats underwent soft tissue trauma and hemorrhagic shock (~90 min) followed by crystalloid resuscitation. Sepsis was induced by cecal ligation and puncture (CLP) 20 h after resuscitation. AMPhi were harvested, and TNF-alpha, IL-6, and macrophage inflammatory protein (MIP)-2 release and serum IL-6 and TNF-alpha levels were measured at 5 h after HCLP. Lung tissues were analyzed for activation of NF-kappaB, myeloperoxidase activity, and wet/dry weight ratio. In control animals, AMPhi were stimulated with LPS with or without inhibitors of NF-kappaB and MAPK. Serum TNF-alpha and IL-6 levels and spontaneous AMPhi TNF-alpha and MIP-2 release were elevated (P < 0.05) after HCLP, concomitantly with the development of lung edema and leukocyte activation. Activation of NF-kappaB increased in lungs from the hemorrhage and CLP group compared with shams. Inhibition of NF-kappaB or the upstream MAPK significantly decreased LPS-stimulated AMPhi activation. Because enhanced release of inflammatory mediators by AMPhi may contribute to ARDS after severe trauma, inhibition of intracellular signaling pathways represents a target to attenuate organ injury under those conditions.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cecum / injuries
  • Chemokine CXCL2
  • Enzyme Inhibitors / pharmacology
  • Extravascular Lung Water
  • Flavonoids / pharmacology
  • Hemorrhage / immunology*
  • Imidazoles / pharmacology
  • In Vitro Techniques
  • Interleukin-6 / blood
  • Lipopolysaccharides / pharmacology
  • MAP Kinase Signaling System / immunology*
  • Macrophages, Alveolar / drug effects
  • Macrophages, Alveolar / enzymology*
  • Macrophages, Alveolar / immunology
  • Male
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism
  • Monokines / metabolism
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism*
  • Peroxidase / metabolism
  • Pyridines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Respiratory Distress Syndrome / immunology*
  • Shock, Septic / immunology*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Chemokine CXCL2
  • Enzyme Inhibitors
  • Flavonoids
  • Imidazoles
  • Interleukin-6
  • Lipopolysaccharides
  • Monokines
  • NF-kappa B
  • Pyridines
  • Tumor Necrosis Factor-alpha
  • Peroxidase
  • Mitogen-Activated Protein Kinases
  • SB 203580
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one